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Abstract Decellularized human dermis has been
used for a number of clinical applications including
wound healing, soft tissue reconstruction, and sports
medicine procedures. A variety of methods exist to
prepare this useful class of biomaterial. Here, we
describe a decellularization technology (MatrA-
CELL) utilizing a non-denaturing anionic detergent,
N-Lauroyl sarcosinate, and endonuclease, which was
developed to remove potentially immunogenic mate-
rial while retaining biomechanical properties. Effec-
tive decellularization was demonstrated by a residual
DNA content of B4 ng/mg of wet weight which
represented[97 % DNA removal compared to unpro-
cessed dermis. Two millimeter thick MatrACELL
processed human acellular dermal matrix (MH-ADM)
exhibited average ultimate tensile load to failure of
635.4 ± 199.9 N and average suture retention
strength of 134.9 ± 55.1 N. Using an in vivo mouse
skin excisional model, MH-ADM was shown to be
biocompatible and capable of supporting cellular and
vascular in-growth. Finally, clinical studies of MH-
ADM in variety of applications suggest it can be an
appropriate scaffold for wound healing, soft tissue
reconstruction, and soft tissue augmentation.
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Introduction
Decellularization technology has been utilized to
remove cellular components in a variety of soft tissues
including cardiovascular allograft and human dermal
matrix to produce bio-implants for clinical applica-
tion. The objectives of the decellularization process
are to remove potentially immunogenic material and
provide a biocompatible scaffold for host cellular and
vascular in-growth (Norton and Babensee 2009).
Following decellularization, the remaining extracel-
lular matrix can also be used as a scaffold for tissue
engineering (Pellegata et al. 2013). Decellularized
cardiovascular tissue has been applied in a variety of
in vivo applications (Ketchedjian et al. 2005a, b;
Hopkins et al. 2009; Elkins et al. 2001a, b; Sievers
et al. 2003; Simon et al. 2003; Hawkins et al. 2003;
Bechtel et al. 2003, 2005; Kasimir et al. 2006;
Steinhoff et al. 2000; Cebotari et al. 2002). Similarly,
human acellular dermal matrix (ADM) has been used
for wound healing, soft tissue reconstruction, and
sports medicine applications. Specifically, human
ADM has been reported to be used clinically for
repair of rotator cuff tears (Wong et al. 2010; Snyder
and Bone 2007; Barber et al. 2008; Burkhead et al.
M. A. Moore (&)  B. Samsell  G. Wallis 
S. Triplett  S. Chen  A. L. Jones  X. Qin
Institute of Regenerative Medicine, LifeNet Health, 1864
Concert Drive, Virginia Beach, VA 23453, USA
e-mail: mark_moore@lifenethealth.org
123
Cell Tissue Bank (2015) 16:249–259
DOI 10.1007/s10561-014-9467-4
2007; Bond et al. 2008; Dopirak et al. 2007), during
which the dermal matrix is typically used to augment a
repair procedure in order to provide biomechanical
strength as well as support directed healing. Also,
Achilles and quadriceps tendon augmentation proce-
dures using human ADM are reported with satisfying
clinical outcomes (Wilkins 2010; Lee 2007, 2008;
Barber et al. 2006). In addition, human ADM is
commonly used for soft tissue reconstruction proce-
dures including primary, staged, and revision breast
reconstruction (Sbitany et al. 2009; Nahabedian 2009;
Salzberg 2006) and hernia repair (Kapfer and Keshen
2006; Albo et al. 2006; Candage et al. 2008; Mitchell
and Cima 2011). Moreover, human ADM is widely
used in the treatment of chronic wounds such as
diabetic foot ulcers (Winters et al. 2008; Randall et al.
2008; Brigido et al. 2004).
In particular, one decellularization technology, Ma-
trACELL (US Patent 6,743,574 (2004)) (LifeNet
Health, Virginia Beach, VA), has been applied to
humanpulmonarypatches,which received510(k) clear-
ance from the FDA and has been in clinical use since
2009 (Lofland et al. 2012). The same MatrACELL
technology is also applied to human dermis and the
resultant ADM is referred to here as MatrACELL
processed human acellular dermal matrix (MH-ADM).
The processing, properties, and potential applications
of MH-ADM are reviewed herein.
The MatrACELL decellularization
and sterilization process
The MatrACELL decellularization process was devel-
oped to minimize the impact of processing reagents on
biomechanical and biochemical properties of the
tissue while still removing cellular components (US
Patents 6,734,018 (2004); 7,338,757 (2008)). MatrA-
CELL- processed tissue is rendered acellular in a
solution of non-denaturing anionic detergent (N-
Lauroyl sarcosinate, NLS), recombinant endonucle-
ase, and antibiotics (including Polymixin B, Vanco-
mycin and Lincomycin). Following decellularization,
the tissue is thoroughly rinsed to remove the decell-
ularization reagents. Next, the bio-implant is
treated with a water replacing agent, such as glycerol
(US Patents 6,293,970 (2001); 6,544,289 (2003);
6,569,200 (2003); 7,063,726 (2006)), prior to final
packaging of the tissue. This allows room temperature
storage and rapid preparation by the end user. Finally,
the bio-implant is terminally sterilized with low temper-
ature, low dose gamma irradiation (Moore et al. 2004).
This final step results in a Sterility Assurance Level
(SAL) of 1 9 10-6 as anticipated for a medical device,
while also inactivating viruses (Moore 2012). The entire
process retains biomechanical and biocompatible (Qin
et al. 2008) properties of the MH-ADM.
Preclinical evaluation of MH-ADM
MH-ADM was assessed via analytical methods,
biomechanical testing, and in vivo analysis. Repre-
sentative study results are presented in this review.
Results from original data sets are not intended to be
generalizable, but add novel information to be
considered in totality with the other studies presented
here.
Histological analysis overview
The MH-ADM process is designed to remove cellular
remnants from tissue. Evidence of decellularization by
histological analysis is demonstrated by the absence of
cell nuclei (Fig. 1) and cell membrane components
such as major histocompatibility complex I (MHC-I)
(Fig. 2). MHC-I plays a vital role in cell immunity, but
is considered an undesirable cellular remnant in tissue
implantation (Steinmetz 1986). This is due to MHC-
I’s capability of activating recipient’s immune
response, specifically CD8? T cells, against the newly
implanted tissue, and, thus, its removal is desirable for
clinically implantable materials.
Analysis of DNA residuals
The DNA content in the MH-ADM was quantified
using Quant-iTTM PicoGreen dsDNA assay kits (Life
Technologies, Inc., Carlsbad, CA) and calculated as
ng/mg tissue weight (Table 1) using one tissue sample
each from three donors (n = 3). Compared to unpro-
cessed dermis, at least 97 % of DNA content was
removed through processing.
In contrast, the post-processing DNA content of
two other commercially available decellularized
human tissues, AlloDerm (LifeCell Corporation,
Branchburg, NJ) and GraftJacketTM (Wright Medical
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Technology, Inc., Arlington, TN), as reported in the
literature (Derwin et al. 2006; Choe and Bell 2001)
were much greater than that found in MH-ADM
(Fig. 3). The content of DNA in MH-ADM was
measured to be 15.97 ± 4.8 ng/mg dry weight. Using
a similar PicoGreen dsDNA Assay (Molecular
Probes), DNA content in GraftJacket was reported to
be an average 134.6 ± 44.0 ng/mg dry weight (Der-
win et al. 2006) and 272.8 ± 168.8 ng/mg tissue for
AlloDerm (Choe and Bell 2001).
Fig. 1 Histological analysis of human skin tissue. a prior to and
b after MatrACELL processing. Hemotoxylin and eosin (H&E)
staining shows nuclear material (blue/purple staining). Note the
presence of stained nuclear material prior to decellularization
(a) in contrast to the lack of nuclear material in the tissue after
the MatrACELL process in MH-ADM (b). (Data on file at
LifeNet Health). (Color figure online)
Fig. 2 Major Histocompatibility Complex I (MHC-I) staining
of human skin tissue a prior to and b after the MatrACELL
process. MHC-I staining was used to detect cells and cellular
remnants. Note the presence of brick-red stained MHC-I
positive cells prior to decellularization (a) in contrast to the
absence of MHC-I staining in the tissue after the MatrACELL
process (b). (Data on file at LifeNet Health). (Color figure
online)
Table 1 DNA content for dermis before and after the MatrACELL decellularization process quantified at minimal, nominal, and
maximal processing parameters




Average DNA in MH-ADM




Minimum 118.18 19.23 1.67 0.16 98.58
Nominal 107.36 13.89 2.78 0.14 97.41
Maximum 132.98 12.24 1.76 0.12 98.68
All DNA content results are presented as ng/mg of wet weight of material (Data on File, n = 3 as 1 sample each from 3 donors,
LifeNet Health). Note the substantial DNA reduction at all parameters as compared to the non-decellularized dermis control. Also
note, in contrast to Fig. 3, these values are presented per wet weight of dermis
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Biomechanical testing overview
Dependent on the intended use, the biomechanical
properties of MH-ADM may be of clinical signifi-
cance, especially in potentially load bearing applica-
tions such as tendon or rotator cuff augmentation. To
assess, suture retention strength was measured as the
force needed to pull out a ‘simple vertical stitch’ of
Arthrex No.2 FiberWire (Arthrex, Inc., Naples, FL)
passed through the tissue 5 mm from the edge (Barber
and Aziz-Jacob 2009). In addition, ultimate load was
determined by pressure clamping two ends of a single
layer of material and elongating to failure. The suture
retention and ultimate load tests were conducted on
two different thicknesses of MH-ADM (2 and
1.5 mm) and GraftJacket as well as SportsMeshTM
(Biomet Sports Medicine, LLC, Warsaw, IN) and
OrthoDAPTTM (Pegasus Biologics, Inc., Irvine, CA)
(Figs. 4, 5). The mechanical testing focused on
different types of soft-tissue augmentation materials
and no control was included. Typically, higher suture
retention strength and ultimate tensile strength were
found in the thicker tissue. While the types of failure
for suture pullout were not noted, the ultimate tensile
tests primarily failed at the midsection. As demon-
strated, the biomechanical integrity of MH-ADM
compared favorably with other materials used in
soft-tissue augmentation procedures.
Moreover, the biomechanical properties of MH-
ADM was investigated (Beitzel et al. 2012) in rotator
cuff augmentation procedures performed on randomly
assigned cadaveric fresh frozen shoulders. Note that
MH-ADM is branded as ArthroFLEX (Arthrex, Inc.,
Naples, FL) in this publication. The study compared
MH-ADM interposed between the bone and tendon as
well as placed on top of the repair. Double-row repairs
without augmentation served as the control. No
significant difference was found in ultimate load to
failure between the control group (348.9 ± 98.8 N)
and the group with interposed MH-ADM
(469.9 ± 148.6 N). However, the group with MH-
ADM placed on top had significantly higher load to
failure (575.8 ± 22.6 N; P = 0.025) than the non-
augmented control (438.9 ± 98.8 N).
Additionally, the biomechanical strength of intact
scapholunate ligaments and the ligaments recon-
structed with 1.5 and 1.0 mm thick MH-ADM (also
described as ArthroFLEX in this published study by
Eshan et al. 2012) was measured in cadaveric tests.
While the intact ligament serving as the control failed
mid-substance during tensile testing, the 1.0 mmMH-
ADM reconstructed ligament failed at the suture-
dermal matrix interface and the 1.5 mm MH-ADM
reconstructed ligament failed at the suture-bone
anchor interface. The authors concluded that the
positive results warrant further clinical investigation
for using MH-ADM as a potential treatment for
chronic scapholunate instability.
Small animal study: in vivo results
MH-ADM was tested using a nude mouse skin
excisional wound model (n = 3). No control of
unprocessed dermis was included as this was intended
only as an assessment of processed dermis. In this
study, a portion of full thickness skin was excised from
the back of a nude mouse and replaced withMH-ADM
and covered with a dressing. After 16 days, the
implanted dermis was removed and examined histo-
logically for cellularity and inflammation. Normal
fibroblast infiltration was observed through the entire
thickness of a representative section of implanted
dermis (Fig. 6) and the surface of the dermis was re-
Fig. 3 Comparison of residual DNA content in three ADM. All
DNA content results are presented as ng/mg of dry weight of
material. Please note this is not a side-by-side experiment, rather
a comparison to the literature. However, all values are
represented as ng/mg dry weight of tissue, and the method of
detection was identical. Asterisk MH-ADM (Data on file at
LifeNet Health, n = 3 as 1 sample each from 3 donors) and
values reported in the literature for: ^ GraftJacket (Derwin et al.
2010), n AlloDerm (Choe and Bell 2001)
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epithelialized partially. Moreover, healthy revascular-
ization was found in the implanted dermis. Minimal
inflammatory cells were found in the graft.
Similar results were found for MH-ADM in a study
by Capito et al. (2012) where the integrative properties
of MH-ADM (also described in the study as DermA-
CELL) and three other ADMs (AlloDermTM, Der-
maMatrixTM (Synthes, Inc., West Chester, PA), and
IntegraTM (Integra LifeSciences Corporation, Plains-
boro, NJ)) were compared in a rat model. Tissue
revascularization, recellularization, and integration
were evaluated at four time points ranging from 7 to
42 days. Out of the four ADMs evaluated, MH-ADM
had the highest cell density measured at 300, 600, and
900 lm from the blood-vessel graft interface at all
time points except Day 42. This difference was
Fig. 4 Suture pullout strength comparison of two thickness
MH-ADM (2 mm* and 1.5 mm*) compared with two thickness
GRAFTJACKET and other surgical mesh products (^). Data
generated for MatrACELL Dermis and all other materials,
respectively was generated at different points in time; however,
the exact same methods, fixtures, material testing machine, and
facility was used for both studies. Asterisk Data on File at
Arthrex (n = 5), ^ Barber and Aziz-Jacobo (2009)
Fig. 5 Ultimate load to failure comparison of two thickness
MH-ADM (2 and 1.5 mm*) is compared with two thickness
GRAFTJACKET and other surgical mesh products (^). Data
generated for MatrACELL Dermis and all other materials,
respectively was generated at different points in time; however,
the exact same methods, fixtures, material testing machine, and
facility was used for both studies. Asterisk Data on File at
Arthrex, ^ Barber and Aziz-Jacobo (2009)
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statistically significant for many of the time points and
distances. Furthermore, MH-ADM had the highest
amount of cellular infiltration at all time points, which
was significantly greater than two of the other ADMs.
Additionally, MH-ADM had a statistically significant
greater amount of blood vessel formation in the tissue
than the other three ADMs at Day 7 and still had a
statistically significant greater amount than two other
ADMs at Day 42. In all three objective evaluations,
MH-ADM compared very favorably with the other
three ADMs tested.
Clinical applications of MH-ADM
Clinical applications of ADMs have been noted in
orthopaedic surgeries, dental and craniomaxillofacial
repairs, soft tissue reconstruction, and wound healing.
Orthopaedic surgeons commonly use ADMs in soft
tissue repair procedures to provide additional
biomechanical strength and improve healing for
rotator cuff repairs, especially for large and massive
tears (Wong et al. 2010; Snyder and Bone 2007;
Barber et al. 2008; Burkhead et al. 2007; Bond et al.
2008; Dopirak et al. 2007). In addition, ADM was
applied to augment Achilles tendon for increased
biomechanical strength, possible enhanced healing,
and reduced return to activity times (Lee 2007, 2008).
For rotator cuff repair, post-operative reports
showed reduced pain and increased motion (Levenda
and Sanders 2012). The authors described an arthro-
scopic technique for performing rotator cuff repair
augmented with MH-ADM in a 10 patient case series
study. At a post operative follow-up of 6 months to
1 year, 9 of 10 patients reported decreased pain and
showed increased motion. The 10th patient was also
progressing well until a fall, 3 months post-operative,
tore the rotator cuff and a total shoulder arthroplasty
was performed. The graft augmentation was found to
be intact during the arthroplasty. In addition, MH-
ADM was also used in repair and augmentation of
Achilles tendon (Fig. 7), quadriceps, and biceps
tendon (Fig. 8).
Bone resorption following tooth extraction requires
immediate ridge augmentation to prevent further
resorption affecting the placement of dental implants
(Wallace 2013). MH-ADM was able to facilitate
guided bone regeneration (GBR) (Wallace 2013) and
soft tissue alveolar ridge augmentation (Al-Hamdan
2011) without the second harvest site morbidity
associated with autografts. In another example of
dental application (Fig. 9), MH-ADM has been
utilized in conjunction with cortical bone particulate
to correct for thin bone implant support. After
4 weeks, there was an increase in tissue profile and
the gum line had healed smoothly. Additionally, MH-
ADM was used to repair temporal depressions by
smoothing over depressions and providing a natural
appearance (Fig. 10).
ADMs have been commonly used for treatment of
acute and chronic wounds. Non-healing, diabetic
ulcers of the lower extremities, particularly the foot,
can be treated with an ADM to achieve complete
healing and integration while avoiding second site
morbidity associated with autografts (Winters et al.
2008; Randall et al. 2008). Yonehiro et al. (2013)
successfully treated diabetic foot ulcers using MH-
ADMwith a substantial wound healing rate of 83 % in
their evaluation of 11 patients with 12 non-healing
Fig. 6 Hematoxylin and eosin staining of MH-ADM explants
using nudemouse skin excisionalmodel. The implantwas in place
for 16 days prior to excision and analysis. Note the presence of
new blood vessels (black arrows) and epithelial layer (open
arrow) (data on file at LifeNet Health). (Color figure online)
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diabetic ulcers. In one of the cases, a 47 year old
female presenting with aWagner Grade 2 non-healing,
diabetic ulcer on the plantar first medial head
(Fig. 11a) was treated with MH-ADM. The patient
went on to a successful outcome with substantial
healing at week 12 after a single application of MH-
ADM (Fig. 11b). A burn wound treated using MH-
ADM demonstrated healing, reduced scarring, and
apparent revascularization and recellularization (Chen
et al. 2012). In this case study, a patient who suffered
from 2nd and 3rd degree burns was initially treated
with antibiotics and dressings and over the next
3 years experienced significant scarring and a corre-
sponding restricted range of motion. Following this
period, the scar tissue was excised and MH-ADM was
applied, and then overlaid with split thickness skin
grafts. At 30 days post-operation, the wound bed
lacked significant scarring and appeared to have rapid
revascularization and recellularization. At 6 months
post-operation, the wound healed with significantly
less scarring and the patient’s range of motion
dramatically improved.
Soft tissue reconstruction procedures of the breast
and plantar heel also commonly utilize ADMs. Two-
stage, primary, and revision breast reconstructions
used ADM to extend the pectoralis muscle and
improve cosmetic appearance while maximizing
available skin and reducing reconstruction time (Sbi-
tany et al. 2009; Salzberg 2006; Ortiz 2014). Using
MH-ADM, a 46 year old woman underwent a bilateral
mastectomy with immediate 2nd stage breast recon-
struction (Fig. 12). Her expanders were filled to
Fig. 7 Use of MH-ADM to augment an Achilles tendon repair. Photo courtesy of Jeffrey Barton, DPM (Delaware Surgery Center,
Dover, DE) showed before (a) and after (b) the augmentation
Fig. 8 Use of MH-ADM to augment a biceps tendon repair.
Photo courtesy of Raffy Mirzayan, MD, Los Angeles, CA
Fig. 9 Use of MH-ADM in conjunction with cortical bone
particulates to correct for the thin bone implant support and to
increase the soft tissue profile in these areas. a Pre-surgery
showing a thin bone ridge. b The application of MH-ADM in
conjunction with implant bone and pins. c 4 weeks post-implant
demonstrating increase in tissue profile and a smoothly healed
gum line. The case photos are courtesy of Paul Rosen, DMD,
MS (Yardley, PA)
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550 cc and after 16 weeks following the mastectomy
they were replaced with 700 cc permanent silicone
implants. The histological analysis (Fig. 13) on biopsy
tissue demonstrated that the MH-ADM was incorpo-
rated into the surrounding tissue. The Hematoxylin
and Eosin staining of the biopsy specimen show
clearly identifiable intact ultrastructure of extracellu-
lar matrix and fibroblast infiltration.
MH-ADM used in tissue replacement of the plantar
heel achieved reduced pain involved with ambulation,
particularly in weight-bearing areas of the heel
(Mulder 2012). In this case series, MH-ADM suc-
cessfully replaced missing tissue of the plantar heel in
3 patients who had previously lost nearly all of their
plantar heel fat pads due to severe motor vehicle
accidents. The first patient exhibited encouraging
results with pain free ambulation at 6 weeks post-
operation and there was continued patient satisfaction
at a 3 months post-operative follow-up visit. At over
1 year post-operation, this patient remained pain free.
The other two patients did not have long term follow-
ups but their initial results were similar to the first
patient, supporting the use of MH-ADM for treating
plantar defects.
Fig. 10 Use ofMH-ADM to repair a temporal depression. a Pre-surgery showing the temporal depression. bThe depression smoothing
following an incision in the hair line and insertion of MH-ADM. The case photos are courtesy of Barry Eppley, MD (Indianapolis, IN)
Fig. 11 Use of MH-ADM for wound repair of a diabetic foot
ulcer. a 47 y.o. female presented with a Wagner Grade 2 non-
healing diabetic ulcer on the plantar first medial head. b The
patient went on to a successful outcomewith a single application
of MH-ADM as noted by the substantial healing at week 12
(Yonehiro et al. 2013: reproduced with permission of the
authors)
Fig. 12 Use of MH-ADM for breast reconstruction. a pre-
operative and b post-operative. In this case, a 46 y.o patient
received a bilateral mastectomy and advanced to the 2nd stage
repair. Her expanders were filled to the full 550 cc and replaced
with a 700 cc silicone implant 16 weeks following mastectomy
(Vashi 2014: reproduced with permission of the author)
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Conclusions
As reviewed here, theMatrACELL process effectively
removes cellular material, including DNA and immu-
nogenic components, yielding an acelluar dermis,
MH-ADM, which retains biomechanical strength and
is biocompatible. Both preclinical and clinical results
support the use of this allograft tissue in a myriad of
clinical applications, including tendon augmentation,
facial reconstruction, wound healing, soft tissue
reconstruction, and dental procedures.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the
original author(s) and the source are credited.
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